Loading... Please wait... Loading... Please wait...
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
The IPO market closed out June with four deals, three of which raised $100+ million. In the pipeline, nine companies submitted initial filings, led by what could be the largest IPO of 2024 to date. We...
On Friday, Alumis Inc ALMS priced its initial public offering at $16/share, the low end of the range of $16 to $18, raising $210 million via 13.13 million shares offering....
Shares of biopharmaceutical firm Alumis opened nearly 16% below their initial public offering (IPO) price in their debut on the Nasdaq on Friday....
Alumis set the pricing of its U.S. initial public offering at $16 per share, the lower end of its price range, valuing it at around $902 million....
Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering...
Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday....
Biopharmaceutical company Alumis Inc. on Monday said it plans to offer 17.65 million shares at an estimated price range of $16 to $18 a share in its upcoming initial public offering. At the midpoint o...
Alumis Inc. has filed for a $100 million IPO to advance its later-Phase trials treatment programs. Lead candidate ESK-001 shows positive trial results for psoriasis treatment, driving potential demand...
